Results 11 to 20 of about 2,891 (162)
Selinexor and COVID-19: The Neglected Warden
Frontiers in Pharmacology, 2022 A novel severe acute respiratory distress syndrome coronavirus type 2 (SARS-CoV-2) has been confirmed as the cause of the global pandemic coronavirus disease 2019 (COVID-19). Different repurposed drugs have been trialed and used in the management of COVID-19. One of these agents was the anti-cancer Selinexor (SXR).
, Nermeen N Welson, Ali I Al-Gareeb
exaly +4 more sources
Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells [PDF]
Hematology ReportsBackground/Objectives: Aurora kinases (AURKs) are key regulators of mitosis, and their dysregulation contributes to plasma cell disorders, including multiple myeloma (MM) and plasma cell leukemia (PCL). Methods: The expression and prognostic relevance of
Seiichi Okabe +6 more
doaj +2 more sources
An evaluation of selinexor’s clinical trial portfolio: a cross-sectional study [PDF]
Therapeutic Advances in HematologyBackground: Cancer drug development is a complex and costly process. Selinexor is a drug that received accelerated approval as a new treatment for relapsed or refractory diffuse-large B-cell lymphoma and multiple myeloma.
Annes Elfar +12 more
doaj +2 more sources
Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study [PDF]
Nature CommunicationsExportin-1 (XPO-1) is related to drug resistance and poor prognosis in solid tumors. Selinexor, an XPO-1 inhibitor, has shown preclinical and clinical activity in sarcomas.
Javier Martin-Broto +14 more
doaj +2 more sources
Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma [PDF]
Cancer ReportsBackground Multiple myeloma (MM) is a blood cancer marked by the abnormal clonal growth of plasma cells. Hypoxia plays a critical role in the progression and treatment resistance of MM. Aims This study investigates the expression of B‐cell/CLL lymphoma 2
Seiichi Okabe +3 more
doaj +2 more sources
Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition [PDF]
Journal of Translational MedicineBackground Acute myeloid leukemia (AML) remains a therapeutic challenge due to drug resistance and relapse. Selinexor, an XPO1 inhibitor, shows limited efficacy as monotherapy, necessitating combination strategies. JQ1, a BET inhibitor targeting MYC, may
Pei-Hong Wang +7 more
doaj +2 more sources
Treatment of multiple myeloma with selinexor: a review
Therapeutic Advances in HematologyOver the last 20 years, breakthroughs in accessible therapies for the treatment of multiple myeloma (MM) have been made. Nevertheless, patients with MM resistant to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies have a
Qianlei Huang +4 more
doaj +3 more sources
Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E
Frontiers in Oncology, 2021 Selinexor is an FDA approved selective inhibitor of the nuclear export protein exportin-1 (XPO1) and causes specific cancer cell death via nuclear accumulation of tumor suppressor proteins.
Jack G. Fisher +8 more
doaj +1 more source
Indian Journal of Medical and Paediatric Oncology, 2021 AbstractSelinexor developed by Karyopharm Therapeutics is the first orally available small-molecule inhibitor of exportin-1 (XPO1). XPO-1 is a protein transporter responsible for the export of macromolecules such as tumor suppressor proteins and oncoprotein mRNAs from the nucleus to the cytoplasm; its inhibition results in blocking of multiple ...
Hridya Jayamohanan +2 more
openaire +1 more source
Combining selinexor with alisertib to target the p53 pathway in neuroblastoma
Neoplasia: An International Journal for Oncology Research, 2022 Neuroblastoma accounts for 15% of cancer-related deaths in children, highlighting an unmet need for novel therapies. Selinexor is a small molecule inhibitor of XPO1.
Rosa Nguyen +5 more
doaj +1 more source